Skip to content
Study details
Enrolling now

Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Advanced Gastric Cancer

University of Chicago
NCT IDNCT04107077ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

21

Study length

about 9 months

Ages

18+

Locations

1 site in IL

What this study is about

Researchers are testing whether HIPEC, a treatment involving chemotherapy delivered directly into the abdomen, can be used more often than standard chemotherapy to improve outcomes in people with advanced gastric cancer that has spread to the lining of the abdominal cavity. The trial will last approximately 265 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Cisplatin
  • 2.Take Mitomycin

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), mitomycin

Drug routes

injection, intravenous, injection (Injection)

Endpoints

Primary: The PD-L1 expression can be upregulated after administration of HIPEC with greater frequency

Secondary: Overall Survival Rate